Investigational drug · Phase 3
AZD0780
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cardiovascular Disease, Dyslipidaemia, Heterozygous Familial Hypercholesterolaemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
4 still active
All registered trials
17
Any phase or sponsor naming "AZD0780"
First trial start
2024
Oct 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD0780", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Cardiovascular Disease
- Dyslipidaemia
- Heterozygous Familial Hypercholesterolaemia
- Atherosclerotic Cardiovascular Disease
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD0780" as an intervention, largest first.
- A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First EventPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07000357 · 15,100 participants (planned) · Start Jun 4, 2025 · Primary completion Oct 26, 2029
Drug: AZD0780; Placebo · For: Cardiovascular Disease
Sites: Athens, Alabama; Birmingham, Alabama; Fairhope, Alabama · 1,452 sites in all
- A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07000123 · 3,103 participants · Start May 28, 2025 · Primary completion Jan 11, 2027
Drug: AZD0780; Placebo · For: Cardiovascular Disease
Sites: Huntsville, Alabama; Irondale, Alabama; Mobile, Alabama · 404 sites in all
- A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFHPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07000136 · 473 participants · Start Jun 10, 2025 · Primary completion Jan 4, 2027
Drug: AZD0780; Placebo · For: Heterozygous Familial Hypercholesterolaemia
Sites: Garden Grove, California; San Diego, California; Miami Lakes, Florida · 133 sites in all
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06834932 · 432 participants · Start Dec 6, 2024 · Primary completion Feb 22, 2027
Drug: Placebo; Rosuvastatin Dose 1 and 2 more · For: Dyslipidaemia
Sites: Baotou, China; Beijing, China; Bengbu, China · 40 sites in all
- A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With DyslipidemiaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06173570 · 428 participants · Start Jan 19, 2024 · Primary completion Sep 30, 2024
Drug: AZD0780; Placebo · For: Dyslipidemia
Sites: Huntsville, Alabama; Lincoln, California; Palm Springs, California · 55 sites in all
- A Study to Assess the Effect of AZD0780 on Ambulatory Blood PressurePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06692764 · 202 participants · Start Oct 30, 2024 · Primary completion Apr 18, 2025
Drug: Placebo; AZD0780 · For: Atherosclerotic Cardiovascular Disease
Sites: Inglewood, California; Northridge, California; Pomona, California · 26 sites in all
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy SubjectsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05384262 · 183 participants · Start May 18, 2022 · Primary completion Jun 14, 2024
Drug: AZD0780; AZD0780 and 5 more · For: Dyslipidemia
Sites: Glendale, California; Brooklyn, Maryland; Harrow, United Kingdom
AstraZenecaAstraZeneca (AZN)
NCT06742853 · 81 participants · Start Dec 20, 2024 · Primary completion Oct 29, 2025
Drug: AZD0780; Ezetimibe and 3 more · For: Dyslipidemia
Sites: Glendale, California; Brooklyn, Maryland; Harrow, United Kingdom
AstraZenecaAstraZeneca (AZN)
NCT07218900 · 76 participants · Start Nov 13, 2025 · Primary completion Sep 3, 2026
Drug: Placebo; AZD0780 and 1 more · For: Dyslipidaemia
Sites: Aramil, Russia; Ivanovo, Russia; Moscow, Russia · 8 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06671405 · 59 participants · Start Sep 25, 2024 · Primary completion Feb 17, 2025
Drug: AZD0780; Itraconazole and 3 more · For: Dyslipidaemia
Sites: Brooklyn, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Comparative efficacy and safety of orally administered PCSK9 inhibitors in patients with Hypercholesterolaemia: a dose-stratified systematic review and network meta-analysis.
Talkhan A, Elkasaby MH, Abou Elezz AM, et al. · Endocrine 2026
- Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.
Vega RB, O'Mahony G, Barbour AM, et al. · Circulation 2026
- Meta-Analysis of Oral PCSK9 Inhibitors for Hypercholesterolemia in Adults: A Systematic Review and GRADE Assessment.
Abomohsen M, Rifai M, Mohamed AE, et al. · Cardiol Rev 2026
- PCSK9 inhibitors: an updated patent review 2024-2025.
Fassi EMA, Albani M, D'Adduzio L, et al. · Expert Opin Ther Pat 2026
- Safety and Efficacy of Oral PCSK9 Inhibitors in Hypercholesterolemia: A Systematic Review and Network Meta-Analysis.
Kamrul-Hasan ABM, Mahajan K, Khalil I, et al. · Endocr Pract 2026
- New frontiers in the treatment of hypercholesterolaemia: oral inhibition of PCSK9.
Arnaboldi L, Tang Z, Ferri N, et al. · Eur Heart J Suppl 2026
Also in development for Cardiovascular Disease
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- OlpasiranAMG 890Phase 33 trials
Amgen · Cardiovascular Disease, Atherosclerotic Cardiovascular Disease
- ClazakizumabLY5724886, CSL300Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Obesity
- Adjuvanted RSVPreF3 vaccinePhase 22 trials
GSK · Cardiovascular Disease, Respiratory Syncytial Virus Infections
- VERVE-102LY4636581Phase 21 trial
Eli Lilly · Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.